Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer

Urology

Volumn 57, Issue 4, 2001, Pages 46-51

  Kelloff, Gary ^a   Lieberman, Ronald ^a   Steele, Vernon ^a   Boone, Charles ^a   Lubet, Ronald ^a   Kopelovich, Levy ^a   Malone, Winfred ^a   Crowell, James ^a   Higley, Howard ^a   Sigman, Caroline ^a  

^a EPN306 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIANDROGEN; ANTIESTROGEN; AROMATASE INHIBITOR; BIOLOGICAL MARKER; CAROTENOID; EFLORNITHINE; ISOFLAVONE; LIPOXYGENASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PRASTERONE; RETINOID; SELENIUM; STEROID 5ALPHA REDUCTASE INHIBITOR; VITAMIN D;

APOPTOSIS; CANCER INVASION; CANCER RISK; CELL DIFFERENTIATION; CHEMOPROPHYLAXIS; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GENETIC PREDISPOSITION; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RELIABILITY;

ANTICARCINOGENIC AGENTS; BIOLOGICAL MARKERS; CLINICAL TRIALS; COHORT STUDIES; HUMANS; MALE; MODELS, ANIMAL; PATIENT SELECTION; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 0034975953     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)00940-7     Document Type: Article

References (29)

1. Introductory remarks: Development of chemopreventive agents for prostate cancer
2. Chemoprevention of prostate cancer: Concepts and strategies
3. Cancer statistics, 2000
4. Androgen metabolism and prostate cancer: Establishing a model of genetic susceptibility
5. Progress in clinical chemoprevention
6. Strategies for identification and clinical evaluation of promising chemopreventive agents
7. Surrogate endpoint biomarkers for Phase II cancer chemoprevention trials
8. Approaches to the development and marketing approval of drugs that prevent cancer
9. Prostate cancer chemoprevention by green tea
10. Prostate cancer chemoprevention by green tea: In vitro and in vivo inhibition of testosterone-mediated induction of ornithine decarboxylase
11. Chemoprevention of hormone-dependent prostate cancer in the Wistar-Unilever rat
12. Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone
13. Lipoxygenase inhibitors as potential cancer chemopreventives
14. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells
15. A non-steroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells
16. The clinical effects of a 5α-reductase inhibitor, finasteride, on benign prostatic hyperplasia
17. Design of the prostate cancer prevention trial (PCPT)
18. Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl) retinamide
19. Evaluation of biomarker modulation by fenretinide in prostate cancer patients
20. Chemoprevention in prostate cancer: The role of difluoromethylornithine (DFMO)
21. Decreased incidence of prostate cancer with selenium supplementation: Results of a double-blind cancer prevention trial
22. Prostate cancer and supplementation with α-tocopherol and β-carotene: Incidence and mortality in a controlled trial
23. Androgen deprivation as a strategy for prostate cancer chemoprevention
24. Intake of carotenoids and retinol in relation to risk of prostate cancer
25. Lycopene supplementation in men with localized prostate cancer (PCa) modulates grade and volume of prostatic intraepithelial neoplasia (PIN) and tumor, level of serum PSA and biomarkers of cell growth, differentiation and apoptosis
26. Prostatic intraepithelial neoplasia (PIN): Current concepts
27. Use of animal models in defining efficacy of chemoprevention agents against prostate cancer
28. The C3(1)/SV40 T antigen transgenic mouse model of prostate and mammary cancer
29. Target populations and strategies for chemoprevention trials of prostate cancer